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Abstract
Background: Radiation induced secondary cancers are a rare but severe late effect after breast conserving therapy.
Intraoperative radiotherapy (IORT) is increasingly used during breast conserving surgery. The purpose of this
analysis was to estimate secondary cancer risks after IORT compared to other modalities of breast radiotherapy
(APBI - accelerated partial breast irradiation, EBRT - external beam radiotherapy).
Methods: Computer-tomography scans of an anthropomorphic phantom were acquired with an INTRABEAM IORT
applicator (diameter 4 cm) in the outer quadrant of the breast and transferred via DICOM to the treatment
planning system. Ipsilateral breast, contralateral breast, ipsilateral lung, contralateral lung, spine and heart were
contoured. An INTRABEAM source (50 kV) was defined with the tip of the drift tube at the center of the spherical
applicator. A dose of 20 Gy at 0 mm depth from the applicator surface was prescribed for IORT and 34 Gy (5 days
× 2 × 3.4 Gy) at 10 mm depth for APBI. For EBRT a total dose of 50 Gy in 2 Gy fractions was planned using two
tangential fields with wedges. The mean and maximal doses, DVHs and volumes receiving more than 0.1 Gy and 4
Gy of organs at risk (OAR) were calculated and compared. The life time risk for secondary cancers was estimated
according to NCRP report 116.
Results: IORT delivered the lowest maximal doses to contralateral breast (< 0.3 Gy), ipsilateral (1.8 Gy) and
contralateral lung (< 0.3 Gy), heart (1 Gy) and spine (< 0.3 Gy). In comparison, maximal doses for APBI were 2-5
times higher. EBRT delivered a maximal dose of 10.4 Gy to the contralateral breast and 53 Gy to the ipsilateral
lung. OAR volumes receiving more than 4 Gy were 0% for IORT, < 2% for APBI and up to 10% for EBRT (ipsilateral
lung). The estimated risk for secondary cancer in the respective OAR is considerably lower after IORT and/or APBI
as compared to EBRT.
Conclusions: The calculations for maximal doses and volumes of OAR suggest that the risk of secondary cancer
induction after IORT is lower than compared to APBI and EBRT.
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The breast is the most common site of cancer in women
and with the wide-spread use of mammography more
than two-thirds of breast cancers are diagnosed at an
early stage [1,2]. Early stage breast cancer carries a bet-
ter prognosis, with outcomes having improved dramati-
cally over the last two decades with a 25% reduction of
breast cancer mortality [3]. Breast-conserving surgery
(BCS) followed by external-beam whole-breast radio-
therapy (EBRT) has become the standard of care in
early breast cancer. Adjuvant EBRT after BCS signifi-
cantly reduces the risk for in-breast tumor recurrence
(IBTR) and improves overall survival over BCS alone
[4-6].
There is clear evidence for the association between
radiation exposure and cancer induction, especially from
epidemiological studies of survivors of the atomic bomb-
ings in Japan [7,8]. The importance of secondary cancer
risks after radiation therapy has been recognized by sev-
eral international organizations, including the Interna-
tional Commission on Radiological Protection (ICRP),
the National Council on Radiation Protection and Mea-
surement (NCRP), and the American Association of
Physicist in Medicine (AAPM). Xu et al. showed that
secondary tumors occur most often in organs that are
closest to radiation fields. Organs located far from the
tumor volume (out-of-field organs) are assumed to
receive low doses of radiation and, therefore, are fre-
quently ignored in treatment planning, even though it is
well known that small radiation doses to these organs
can induce secondary cancers as well [9,10].
Radiation therapy for breast cancer has changed sig-
nificantly in the last decades, regarding radiation type,
application of treatment, treatment duration and 3D
dose distributions. For early stage breast cancer, multi-
ple techniques have been developed recently for acceler-
ated partial breast irradiation (APBI) such as high dose
rate brachytherapy (HDR-BT) [11,12], permanent breast
seed implant (PBSI) [13], intraoperative radiotherapy
(IORT) using 50 kV X-rays (TARGIT) [14] or electrons
(ELIOT) [15], and 3D conformal radiotherapy [16]. All
techniques share a potential advantage in patient accep-
tance due to higher convenience. Regardless, advances
in breast radiotherapy treatment techniques should con-
tinue to focus on reducing the dose to critical structures
(lung, heart, and contralateral breast) as minimal as pos-
s i b l et or e d u c et h er i s ko fs e c o n d a r ym a l i g n a n c ya n do f
late cardiac and pulmonary complications.
IORT with low-energy X-rays (TARGIT - TARGeted
Intraoperative radioTherapy) is an innovative technique
that can be used during breast-conserving surgery as a
sole treatment for low risk patients or as a tumor bed
boost followed by external beam radiotherapy (EBRT)
[14,17]. The TARGIT A study has demonstrated the
non-inferiority of IORT using the TARGIT approach in
selected patients as compared to standard external beam
radiotherapy [14]. The purpose of the present analysis
w a st oc a l c u l a t ed o s e st oO A Ra n dt oe s t i m a t es e c o n d
cancer risks after IORT compared to other modalities of
breast irradiation (APBI, EBRT).
Methods
Three different breast irradiation protocols were selected
which are currently used during or after breast conser-
ving surgery in clinical practice or clinical studies. Please
note that the target volume concepts and the prescrip-
tion doses are different between the respective methods:
(1) IORT: single dose of 20 Gy (Intrabeam) prescribed
at the applicator surface (0 mm) as used in the TARGIT
A trial [14]. The target volume concept is represented
by the sphere of equivalence [18].
(2) APBI: accelerated partial breast irradiation with 34
Gy in 10 fractions (5 days × 2 × 3.4 Gy) prescribed at
10 mm depth from the Intrabeam applicator surface
[19] as used with Mammosite [11]. The planning target
volume is 1 cm breast tissue around the excision cavity.
(3) EBRT: standard three dimensional conformal
radiotherapy with 50 Gy in 25 fractions to the whole
breast using two tangential fields with wedges. Here, the
planning target volume is considerably larger and
includes the whole breast including a safety margin.
CT scans were obtained from a CT-simulator (Brilli-
ance CT Big Bore, Philips, Cleveland, OH, USA) of an
anthropomorphic phantom (Model: 002LFC, CIRS,
USA) having a single breast attachment as shown in Fig-
ure 1. An Intrabeam applicator (4 cm diameter) (Carl
Zeiss Surgical, Oberkochen, Germany) was inserted in
the upper outer quadrant of the breast.
All images were transferred via DICOM to the treat-
ment planning system (Nucletron Plato Brachytherapy
planning system, version 14.2.6, Veenendaal, The Neth-
erlands). The organs at risks (OARs) such as ipsilateral
breast, contralateral breast, ipsilateral lung, contralateral
lung, spine and heart were defined and contoured
accurately.
For isodose distribution of IORT and APBI, we used
the spherical Intrabeam applicator with 4 cm in dia-
meter. We defined an Intrabeam source (50 kV) in the
treatment planning system and placed the source at the
center of the spherical applicator. By using the CT
images of the breast phantom, only one source-dwell
position was planned to deliver a dose of 20 Gy at 0
mm from the applicator surface for IORT and 34 Gy in
10 fractions (5 days × 2 × 3.4 Gy) at 10 mm depth from
the applicator surface for APBI (see Figure 1). The iso-
dose lines of 1%, 5%, 10%, 50%, 100% were selected by
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A P B Ia ss h o w ni nf i g u r e s1a n d1 .T h e3 Dd o s ed i s t r i -
bution was then calculated and stored for evaluation
purposes.
For conventional EBRT, all planning CT images were
transferred via DICOM to Oncentra Masterplan (version
3.3, Nucletron, Sweden) for the 3D dose calculation.
The OARs were contoured in the Oncentra Masterplan
software in the same way as for IORT and APBI in the
Plato brachytherapy planning software. Using CT based
3D treatment planning; a total dose of 50 Gy in 2 Gy
fractions was prescribed to the whole ipsilateral breast
using standard tangential treatment portals (6 MV,
Synergy, Elekta, Crawley/UK) as shown in figure 1. Each
field included a wedge to achieve a homogeneous dose
distribution inside the breast volume. For the compari-
son of IORT, APBI and EBRT, we selected the same iso-
dose lines of 1%, 5%, 10%, 50%, 100%.
After calculation of the dose distribution, Dose-
Volume Histograms (DVHs) were calculated for all
OARs for complete evaluation of the treatment plan for
all three techniques (IORT vs. APBI vs. EBRT). The
mean and maximum doses and volumes receiving more
than 0.1 Gy and 4 Gy of the OARs were calculated and
compared. Some values such as 0.1 Gy to 0.3 Gy for
IORT and 0.1 Gy to 0.5 Gy for APBI were calculated by
option polynomial with the standard Software Excel™
(Microsoft Corporation, Redmond, Seattle, USA),
because in Plato brachytherapy system, it was not possi-
ble to calculate values for lower doses and also volumes
according to these doses.
The lifetime probabilities of developing fatal secondary
malignancies were calculated per Sv absorbed in breast
and lung using the National Council on Radiation Pro-
tection and Measurements (NCRP) report 116 Table
Seven Part Two page 32 [20], according to a similar
study by Pignol et al. [21].
Results
Figure 1 shows the comparison of the isodose distribu-
tions from the three breast radiotherapy techniques.
O b v i o u s l yt h e r ea r el a r g ed i f f e r e n c e si nt h ed o s ed i s t r i -
butions and especially in the low doses regions delivered
to the OARs. Compared with IORT, both APBI and
EBRT, deliver higher doses to the ipsilateral lung and
heart. Both IORT and APBI deliver negligible doses to
the spine, contralateral lung and contralateral breast as
compared to EBRT.
DVHs provide dose volume information for the organs
contoured in the treatment planning system. Figure 2
shows the dose volume contribution to the ipsilateral
breast from the different breast radiotherapy techniques.
Most of the volume of the ipsilateral breast receives almost
Figure 1 Planning CT of an anthropomorphic phantom with an
Intrabeam applicator in the upper outer quadrant of the right
breast showing calculated isodoses (1%-100%). (a) IORT (20 Gy
at 0 mm, 50 kV). (b) APBI (34 Gy at 10 mm, 50 kV). (c) EBRT (50 Gy,
6 MV).
Figure 2 Cumulative DVH for ipsilateral breast for IORT, APBI
and EBRT.
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Page 3 of 9100% dose by EBRT. In contrast, a marked dose reduction
to large volumes is seen in the ipsilateral breast by the par-
tial breast irradiation techniques IORT and APBI. How-
ever, due to the steep dose gradient and the prescription
to 10 mm tissue depth, APBI delivers the highest maximal
dose to the ipsilateral breast. Figure 3 shows the compari-
son of DVHs of ipsilateral lung and heart by IORT, APBI
and EBRT. Ipsilateral lung and heart receive considerably
higher doses by EBRT as compared to IORT. Interestingly,
APBI results in a higher maximal dose to the heart com-
pared to EBRT even for a case with right breast cancer.
The doses to relevant volumes of critical structures like
ipsilateral lung and heart are minimal and can be consid-
ered negligible by IORT.
To estimate the risk of stochastic and deterministic
normal tissue effects, table 1 compares the mean and
maximal doses to selected organs during IORT, APBI
and EBRT. Mean and maximal doses in the OARs deliv-
ered by IORT are consistently lower as compared to
APBI and EBRT. The maximal dose to the heart is
larger during APBI than after EBRT and considerably
smaller using IORT. The external beam radiotherapy
yields the largest maximal dose in the ipsilateral lung
(53 Gy), contralateral lung (1.0 Gy) and contralateral
breast (10.4 Gy). Due to very low mean doses in the
spine, contralateral lung and contralateral breast after
IORT and APBI with less than 1.5% of the prescribed
d o s e ,i tw a sn o tp o s s i b l et oc a l c u l a t ee x a c tv a l u e sf o r
these OARs with the Plato brachytherapy system.
As an estimate for secondary cancer risk, table 2 com-
pares the corresponding volumes of OARs receiving
more than 0.1 Gy and 4 Gy from the different breast
radiotherapy protocols. The ipsilateral breast shows a
smaller volume for doses higher than 0.1 Gy and 4 Gy
after IORT than in the case of APBI and EBRT. There
is a larger volume with doses > 4 Gy within the ipsilat-
eral lung for EBRT than after APBI, while this dose is
not reached by IORT at all. For external beam radio-
therapy, almost the total volume for spine, contralateral
lung and contralateral breast receive doses of > 0.1 Gy
while these organs show negligible volumes receiving
more than 0.1 Gy by IORT and APBI. With the EBRT
technique, about 10% of the contralateral breast receives
doses > 4 Gy. There is no volume for heart, spine and
contralateral lung receiving doses higher than 4 Gy from
these radiotherapy protocols (IORT vs. APBI vs. EBRT).
Table 3 compares the secondary cancer risk estimates
from these breast radiotherapy techniques. We calcu-
lated the secondary cancer risk from maximal doses
where mean doses were not available but obviously then
this can only be an upper estimation of the risk. In the
case of ipsilateral lung, secondary cancer risk (0.02%) is
considerably less for IORTa sc o m p a r e dt oA P B Ia n d
EBRT. The secondary cancer risk for contralateral breast
(< 0.06%) calculated from maximal dose for IORT is
lower than for APBI and EBRT. The calculated risk
from EBRT for the ipsilateral and contralateral lung is
about 2.9% and 0.2%.
Discussion
Over the past several years, multiple studies have estab-
lished the feasibility of IORT for the treatment of
Figure 3 Cumulative DVH for ipsilateral lung and heart for
IORT, APBI and EBRT.
Table 1 Maximal and mean doses for OARs for IORT, APBI and EBRT.
Dose to Organs IORT APBI EBRT
Mean dose (Gy) Max dose (Gy) Mean dose (Gy) Max dose (Gy) Mean dose (Gy) Max dose (Gy)
Ipsilateral Breast 2.2 20 10.4 102 49.0 55.3
Contralateral breast ....... < 0.3 ........ < 0.56 1.1 10.4
Ipsilateral Lung 0.03 1.8 0.13 7.4 3.4 53.0
Contralateral lung ...... < 0.3 ........ < 0.56 0.24 1.0
Heart 0.01 1 0.06 3.8 1 2.8
Spine ....... < 0.3 ........ < 0.56 0.24 0.5
Doses < 1.5% of the prescribed dose cannot be shown by Plato (......).
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the intraoperative approach is to deliver a high dose to
parts of the breast, i.e. the tissue around the tumor cav-
ity up to a depth of 1-2 cm, within a short overall treat-
ment time (APBI - accelerated partial breast irradiation).
In contrast to other approaches, where the dose is pre-
scribed to a conventional PTV margin, in the TARGIT
approach [14,17] using a low-energy X-ray device (Intra-
beam), the dose is not prescribed to a defined depth.
The highest dose is at the applicator surface and it
decreases with increasing tissue distance from the appli-
cator. This steep dose fall-off results in very low doses
to surrounding organs and eliminates the need for spe-
cific radiation protection measures. Reports about local
tumor control and acute and long-term side effects have
been published with follow-up times up to ten years. It
is obvious, that there are no clinical analyses about sec-
ond cancer induction using this approach due to the
limited time span of clinical availability. To estimate the
long term risks of breast radiotherapy including second-
ary cancer, we performed dosimetric comparisons of
IORT using Intrabeam with selected other breast radio-
therapy techniques.
High-dose radiation increases the risk of second
malignancy after breast or chest-wall irradiation (e.g.
Surveillance Epidemiology and End Results (SEER) data-
base) [22] (see table 4 for overview). Hall et al. showed
that the risk increases with a linear proportionality to
dose [23,24] between low doses and moderate doses
(from 0.1 Gy to 3 Gy). Little [25] distinguished the dif-
ference between A-bomb survivors and patients treated
by radiotherapy to the role of cell killing at doses higher
than 2 Gy but the analysis of Le Pogam et al. [26] did
not provide evidence for a role of cell killing. Other
reports suggested a threshold at about 0.6 Gy in adults
after fractionated radiotherapy and after an acute irra-
diation in children at 0.1 Gy [26,27]. We therefore
chose volumes receiving more than 0.1 Gy (threshold)
and 4 Gy (relevant dose) for comparison in our analysis.
There is a wide variation of risk estimates for second
cancer in the literature. Lifetime breast cancer induction
risk for a breast exposed to 1 Gy is approximately 5% if
irradiated at the age of < 35, < 3% at the age of 35-45,
and much less at an older age [10]. For a phantom case
study [21] the incremental risk of secondary cancer was
calculated for the tangential whole breast technique
with wedge compensators based on National Council on
Radiation Protection and Measurements (NCRP) report
116 [20] as 0.34% which is likely to be undetectable
compared to the observed frequency of contralateral
breast cancer of about 7% at 10 years and 10% at 15
years [28,29]. The causes of contralateral breast cancer
amongst breast cancer patients given radiotherapy are
less obvious. A large study by Kirova et al. did not show
an increased risk of contralateral breast cancer for those
receiving radiotherapy [30]. Obedian reported no signifi-
cant difference in the occurrence of contralateral breast
cancer at 15 years in a retrospective series of 2,416
patients treated with breast conserving surgery and adju-
vant radiotherapy or mastectomy without radiotherapy
[29].
The calculated risk for lung cancer after EBRT in a
phantom study was 0.49% [21]. This value was slightly
higher but of the same order of magnitude than the
Table 2 Volumes of OAR receiving doses greater than 0.1 Gy and 4 Gy which are doses considered to be relevant for
induction of secondary cancers.
IORT APBI EBRT
%Vol > 0.1 Gy %Vol > 4 Gy %Vol > 0.1 Gy %Vol > 4 Gy %Vol > 0.1 Gy %Vol > 4 Gy
Ipsilateral Breast 84.5 18.1 88.2 54.4 99.9 99.9
Contralateral breast < 1 0 < 1 0 97.7 1.3
Ipsilateral Lung 4.5 0 5.0 1.3 98.8 10.1
Contralateral lung < 10< 10 8 7 0
Heart 1.8 0 4.2 0 98 0
Spine < 10< 10 9 2 0
Table 3 Lifetime risk of secondary cancers for organs doses from different breast radiotherapy techniques.
Organs Probability (%/Sv) IORT APBI EBRT
Contralateral Breast 0.20 (< 0.06%*) (< 0.11%*) 0.22% (< 2.08%*)
Ipsilateral lung 0.85 0.02% 0.11% 2.9%
Contralateral lung 0.85 (< 0.25%*) (< 0.47%*) 0.2% (< 0.85%*)
The probability per Sievert was taken from the National Council on Radiation Protection and Measurements (NCRP) Report 116. Mean organ doses were used for
the calculation of secondary cancer risk (*maximal doses were used where mean doses were not available). Note that RBE effects were not taken into account,
which may be up to a factor of 1.3 - 3 for IORT (see discussion).
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Zablotska on a cohort of 260,000 patients included in
the Surveillance Epidemiology and End Results (SEER)
database [31]. For the particular case of the irradiation
of the lung during the treatment for breast cancer,
Inskip et al. [32] have concluded that for an average
dose of 10 Gy the risk for radiation-induced secondary
cancer is around 0.9% which represents about a twofold
i n c r e a s eo fr i s ko fp u l m o n a r yn e o p l a s i aa m o n g1 0 - y e a r
survivors of breast cancer.
The calculated doses to the OAR in our study are
considerably lower with IORT as compared to standard
tangential EBRT and therefore the estimated risk for
secondary cancer should be considerably lower. How-
ever, one may assume that novel EBRT approaches
using tangential intensity modulated radiation therapy
(IMRT) replacing wedges may yield lower scattered
doses in the range of a factor of 2. In contrast, rota-
tional IMRT techniques or isotropic multi-field IMRT
may be associated with a dose bath, i.e. a large volume
receiving low doses [24]. Intensity-modulated radiother-
apy has been developed to improve the homogeneity of
the dose distribution within the target volume, but, by
contrast with 3D radiotherapy, is generally associated
with a larger volume of healthy tissue being irradiated
to low doses. This is due to an increase in the number
of beams used with this technique and the number of
monitor units, resulting in radiation leakage, and an
increase in the total body exposure. These two factors
could lead to an increase in the risk of second cancers
[23,24]. A study by Lettmaier et al. showed that maxi-
mum doses received by different volumes of the heart,
the lungs and the skin, and dose values for all OAR are
consistently lower for partial breast irradiation using
brachytherapy than those for whole breast irradiation
with EBRT [33].
Another important point for comparative risk estima-
tion is that low energy X-rays have an increased relative
biological effectiveness (RBE). The maximal doses to
OARs in our study are 3 - 20 times lower after IORT as
compared to EBRT. RBE values of 1.3 up to 3 have been
reported for Intrabeam [18,19,34] which would still
result in lower maximal biological doses as compared to
EBRT. Additional uncertainty of the risk estimation is
based on the different dose rate and time schedule i.e.
fractionated application over 6 weeks vs. single dose.
The estimation of secondary cancer risks after breast
cancer therapy is also complicated by the fact that not
only radiotherapy may be associated with mutagenesis.
Several studies have reported an increased risk for mye-
loid leukemia (AML) or myelodplastic syndrome (MDS)
in breast cancer patients treated with adjuvant che-
motherapy. Praga et al. [35] reviewed 7110 patients trea-
ted with epirubicin and cyclophosphamide in 19
randomized clinical trials. At a median follow-up of 8
years, the cumulative probability of AML or MDS was
0.55%. The risk increased in relation to the cumulative
doses of both agents. Patients who received cumulative
Table 4 Secondary cancer risk after radiotherapy for breast cancer
Authors, journal, year No. of patients Follow up
time
organs Risk for secondary
cancer
Berrington de Gonzalez
Br J Cancer
(2010) [22]
182,057
69,181 treated with
radiotherapy
13 years Lung, oesophagus, pleura, bone and soft
tissue
Contralateral breast
RR = 1·38 (95% CI 1·26-
1·51)
RR = 1.09 (95% CI 1.04-
1.15)
Kirova
Int J Radiat Oncol Biol
Phys
(2007) [53]
16,705
13,472 treated with
radiotherapy
10 years Lung
Contralateral breast
RR = 3.09 (95% CI 1.12-
8.53)
RR = 1.1 (95% CI 0.96-
1.27)
Roychoudhuri
Br J Cancer
(2004) [54]
64,782
33,763 received radiotherapy
> 10 years Lung RR = 1.65 (95% CI 1.05-
2.54)
Zablotska
Cancer
(2003) [31]
260,541
76,467 treated with
radiotherapy
10 years lung 0.30%
RR = 2.06 (95% CI 1.53-
2.78)
Prochazka
Eur J Cancer
(2002) [55]
141,053
141,053 treated with
radiotherapy
> 10 years lung RR = 2.3 (95% CI 1.97-
2.63)
Fowble
Int J Radiat Oncol Biol
Phys
(2001) [28]
1,253
977 treated with radiotherapy
10 years Contralateral breast 7%
Obedian
J Clin Oncol
(2000) [29]
2,416
1,029 treated with radiotherapy
15 years Contralateral breast 10%
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(720 and 6300 mg/m
2, for epirubicin and cyclophospha-
mide, respectively) had an 8-year probability of 0.37%
(95% confidence interval (CI) 0.13% to 0.61%) compared
with 4.97% (95% CI 2.06% to 7.87%)) for those who
received higher doses [35,36]. Furthermore, oral bispho-
sphonates have been associated with an increased risk of
esophageal cancer. Green and colleagues, who used the
UK’s General Practice Research Database compared the
frequency of oral bisphosphonate exposure in cases ver-
sus matched non-cases. They found that one (or more)
prescription for oral bisphosphonates increased the risk
of esophageal cancer by 30%; 10 or more prescriptions
nearly doubled the risk. They found a globally increased
risk (Relative Risk (RR): 1.3; 95% Confidence Interval
(95% CI): 1.02-1.66), and an almost doubled risk in
p a t i e n t sw h ou s e da tl e a s t1 0p r e s c r i p t i o n s( R R=1 . 9 3 ;
95% CI 1.37-2.70) or in those who were treated for
more than 3 years (RR: 2.24; 95% CI: 1.47-3.43) [37,38].
Radiation induced late heart disease has been observed
in patients who received therapeutic doses of about ≥ 35
Gy to partial volumes of the heart [39]. Recent studies
based on atomic bomb survivors also suggest a relation-
ship between cardiac mortality and low radiation doses
in the range of ≤ 4 Gy [7,40-42]. Several clinical case
series found no clear evidence of late cardiac mortality
after breast radiotherapy [43-46]. In contrast, a recent
critical view published by Schultz-Hector suggests that
acute single doses of 1-2 Gy to the heart increased the
risk of developing ischemic heart disease significantly
[ 4 7 ] .C o n s i d e r i n gt h i s ,i ti so fi n t e r e s tt on o t i c et h a t
APBI delivers a higher maximal dose to parts of the
heart as compared to IORT and EBRT. A significantly
better sparing of the high-dose volume of the heart in
selected early breast cancer patients with unfavourable
thoracic geometry has been reported by the use of mul-
tifield IMRT [48-50]. Compared to three dimensional
conformal radiotherapy (3DCRT), multifield IMRT
reduced the heart volume receiving ≥ 30 Gy by 87%
[48], or ≥ 35 Gy by 81% [49].
Modelling cardiac toxicity is complicated for several
reasons, as discussed in the review by Gagliardi et al.
[51], including organ at risk definition (heart or left ven-
tricle or myocardium), scarce dosimetric data for histor-
ical techniques, and a latency of symptoms of > 10
years. Although the mean excess NTCP (cardiac mortal-
ity) for tangent RT in their series of 100 consecutive
patients was about 2%, they reported a subset of patients
with an excess NTCP of 4-5%. In a previous report from
our group we worked with a cohort of patients selected
because of their unfavorable anatomy, which is probably
comparable to their group with the greatest NTCP.
Using multifield IMRT a similar order of magnitude of
NTCP reduction (3-4% to 0.05% for their sample patient
and 6.03% to 0.25% for our patients) could be achieved
[48,50,52].
Conclusions
This is to our knowledge the first report about the esti-
mation of second cancer risk using TARGIT IORT (50
kV X-rays) for breast cancer. In comparison with APBI
and EBRT, the calculated mean and maximal doses for
OAR are lower for IORT, as well as the high dose
volumes (> 4 Gy). This would suggest that the risk of
secondary cancer induction after IORT is lower than
after APBI or EBRT.
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